A phase 2 study of Relacorilant to treat patients with antipsychotic-induced weight gain and non-alcoholic steatotic hepatitis ("NASH")

Next Previous
Trial Profile

A phase 2 study of Relacorilant to treat patients with antipsychotic-induced weight gain and non-alcoholic steatotic hepatitis ("NASH")

Planning
Phase of Trial: Phase II

Latest Information Update: 26 Feb 2018

At a glance

  • Drugs Relacorilant (Primary)
  • Indications Non-alcoholic steatohepatitis
  • Focus Therapeutic Use

    • Most Recent Events

    • 26 Feb 2018 New trial record
    • 22 Feb 2018 According to a Corcept Therapeutics media release, company is planning to initiate this study by year end 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top